The advent of prostate-specific antigen (PSA) testing in the early 1980s revolutionized the
diagnosis of prostate cancer. As a result of PSA testing, there has been a surge in the …

Two large randomized trials on prostate cancer screening have recently reported their 10-
year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and …

Introduction for screening for prostate cancer as a healthcare policy is desirable provided its
effectiveness can be shown in terms of decreasing prostate cancer mortality at an …

OBJECTIVE To describe the results of the first four rounds (T0‐T3) of prostate cancer
screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial …

Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer …

Prostate cancer is the most common cancer and the second leading cause of cancer-related
deaths in American men. Although the use of the prostate-specific antigen (PSA) test for …

Screening and treatment for prostate cancer is controversial. In the absence of randomized
trials, several prominent medical organizations in the United States and Europe have …

Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …

In two large randomized trials, researchers examined the effect of annual prostate-specific–
antigen (PSA) screening on the rate of death from prostate cancer and found that it was …

Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary
(PLCO) cancer trial in the USA and the European Randomized Screening for Prostate …